Metabolisme-forskning
GLP-1- og GIP-receptoragonister til metabolisk forskning. Nedenfor er den publicerede litteratur for hver forbindelse inden for dette område — 206 studier i alt, 103 af dem publiceret siden 2023, alle linket til deres kildepost.
- MetabolismeKun præklinisk
5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) er en cellepermeable småmolekylær hæmmer af nicotinamid N-methyltransferase (NNMT), enzymet der methylerer nicotinamid og derved forbruger S-adenosylmethionin og afleder nicotinamid væk fra NAD+ salvage. Interessen for målet fulgte efter en Nature-rapport fra 2014, hvori antisense knockdown af NNMT i fedtvæv og lever beskyttede mus mod diætinduceret fedme. Efterfølgende arbejde karakteriserede 5-amino-1MQ og beslægtede quinolinium-hæmmere i diætinducerede overvægtige gnavere, aldret skeletmuskulatur, sarcopeni- og perifere arteriesygdomsmodeller, sammen med medicinal-kemi- og hæmningsmekanismestudier. Det publicerede evidensgrundlag er udelukkende præklinisk; ingen humant klinisk forsøg med 5-amino-1MQ er rapporteret i den peer-reviewede litteratur.
- Studier
- 15
- Siden 2023
- 8
- Nyeste
- 2026
- MetabolismeTidlig klinisk
AOD-9604
AOD-9604 er et syntetisk hexadecapeptid, der svarer til den C-terminale lipolytiske domæne af humant væksthormon (Tyr-hGH 177-191, almindeligvis skrevet som hGH fragment 176-191). Præklinisk arbejde publiceret mellem 1993 og 2001 karakteriserede fragmentets virkninger på lipolyse, lipogenese og fedtoxidation i gnaver-modeller og rapporterede, at disse virkninger indtraf uden målbar interaktion med hGH-receptoren eller IGF-1-elevation. Forbindelsen gik efterfølgende ind i humane fedme-forsøg, hvis poolede sikkerheds- og tolerabilitetsdata blev publiceret i 2013, og ikke-kliniske genotoksicitets- og kroniske toksikologidata, der understøttede en fødevareingrediens-position, blev publiceret i 2014; ingen effektivitetsstudie er fremkommet som en selvstændig peer-reviewed rapport. Senere litteratur er domineret af anti-doping analytisk kemi, et kanin-intraartikulært osteoarthritis-studie og narrative oversigter over peptider i ortopædi og sportsmedicin.
- Studier
- 17
- Siden 2023
- 4
- Nyeste
- 2026
- MetabolismeGodkendt lægemiddel
Lemon Bottle
Injectable lipolysis has been studied mainly as deoxycholic acid (ATX-101), a synthetic bile salt approved for submental fat reduction on the basis of two phase 3 randomised trials (REFINE-1 and REFINE-2), and as compounded phosphatidylcholine/sodium deoxycholate formulations, which were never approved for this use. Preclinical work indicated that the deoxycholate component, acting as a detergent that disrupts cell membranes, was the principal adipocytolytic agent rather than phosphatidylcholine. The reported adverse-event profile includes injection-site swelling and induration, marginal mandibular nerve paresis, skin ulceration and necrosis, fibrosis, and post-procedural infection, with animal data documenting demyelinating nerve injury after intrafascicular exposure. The branded product marketed as 'Lemon Bottle' was not identified in any peer-reviewed clinical or mechanistic study, so the evidence described here relates to deoxycholic acid and phosphatidylcholine/deoxycholate rather than to that specific formulation.
- Studier
- 39
- Siden 2023
- 15
- Nyeste
- 2026
- MetabolismeKlinisk
Lipo-C Fat Blaster
Lipo-C refers to a compounded injectable mixture whose typical constituents are methionine, inositol, choline, L-carnitine and vitamin B12. The published literature addresses these substances individually rather than as a combined injection, and the bulk of that evidence comes from oral supplementation trials and observational nutrition studies. Component-level findings span body-composition meta-analyses for L-carnitine, hepatic steatosis work for choline, insulin-sensitivity and gestational diabetes meta-analyses for myo-inositol, small human studies of dietary methionine restriction, and status and route-of-administration analyses for vitamin B12. Evidence generated for one component under one route and dose does not transfer to a multi-ingredient injectable preparation.
- Studier
- 35
- Siden 2023
- 13
- Nyeste
- 2026
- MetabolismeKlinisk
Retatrutide
Retatrutide (LY3437943) is an investigational single-peptide triple agonist of the GIP, GLP-1 and glucagon receptors, first described in preclinical rodent pharmacology and phase 1 studies in 2022 and subsequently in phase 2 randomised trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Phase 2 reports documented dose-dependent reductions in body weight, HbA1c and liver fat content, alongside predominantly gastrointestinal adverse events. A registrational phase 3 programme (TRIUMPH) and a separate TRANSCEND programme in type 2 diabetes and chronic kidney disease followed; the first phase 3 readout (TRANSCEND-T2D-1) was published in The Lancet in 2026, and the 80-week TRIUMPH-1 (obesity without diabetes) and TRIUMPH-2 (obesity with type 2 diabetes) trials were published in September 2026, reporting larger mean weight reductions than placebo with predominantly gastrointestinal adverse events. As of October 2026 the compound was not an approved medicine in any jurisdiction.
- Studier
- 23
- Siden 2023
- 21
- Nyeste
- 2026
- MetabolismeGodkendt lægemiddel
Tesamorelin
Tesamorelin (TH9507) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates endogenous, pulsatile growth hormone secretion via the GHRH receptor. It was evaluated in large multicentre phase 3 trials in people with HIV and excess abdominal fat, where visceral adipose tissue was the primary endpoint, and was subsequently approved for HIV-associated lipodystrophy. Later investigator-initiated trials extended the work to hepatic fat in NAFLD/MASLD, to neurocognitive endpoints in mild cognitive impairment and in HIV, and to lean mass and physical function. Recent literature is dominated by meta-analyses of the HIV lipodystrophy trials, MASLD reviews, and preclinical GHRH-agonist neurobiology.
- Studier
- 34
- Siden 2023
- 13
- Nyeste
- 2026
- MetabolismeGodkendt lægemiddel
Tirzepatide
Tirzepatide (LY3298176) is a fatty acid-modified synthetic peptide that agonises both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors from a single molecule. Receptor pharmacology published between 2018 and 2020 characterised it as imbalanced towards the GIP receptor and biased at the GLP-1 receptor, and rodent work linked that profile to reduced food intake and body weight. Clinical development proceeded through a phase 2 trial against dulaglutide, the SURPASS glycaemic-control programme in type 2 diabetes and the SURMOUNT body-weight programme in obesity, followed by dedicated trials in obstructive sleep apnoea, metabolic dysfunction-associated steatohepatitis and heart failure with preserved ejection fraction. SURPASS-CVOT, an active-comparator cardiovascular outcomes trial in more than 13,000 patients, reported in 2025. Tirzepatide is an approved prescription medicine for type 2 diabetes and for weight management in several jurisdictions, and gastrointestinal adverse events dominate the tolerability profile reported across the programme.
- Studier
- 43
- Siden 2023
- 29
- Nyeste
- 2026
Senest publiceret forskning
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation
Trends in Pharmacological Sciences · oversigt over NNMT-hæmmerfarmakologi, medicinal kemi og translationelle perspektiver
PubMed · 42067476Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis
Cartilage · narrativ oversigt over chondroinduktive peptider på tværs af in vitro og dyr-osteoarthritis-modeller (online først september 2024; tildelt et 2026-nummer)
PubMed · 39291443Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Sports Medicine · narrativ gennemgang der kontrasterede godkendte og ikke-godkendte peptider i sportsmedicin, AOD9604 blandt dem
PubMed · 41966639The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology · narrativ gennemgang af GH-IGF1-akse-peptider herunder GHRH-analoger, sekretagoger og hGH-fragmenter
PubMed · 42395176Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Journal of the American Academy of Orthopaedic Surgeons: Global Research and Reviews · narrativ gennemgang af peptider anvendt i håndtering af ortopædiske skader
PubMed · 41490200Dermal Necrosis and Chronic Abscess Formation Following Fat Dissolving Injections Administered by a Non-Medical Practitioner: A Case Report
· preprint, not peer reviewed; single case, 33-year-old woman given injections of a lipolytic product purported to be 'Lemon Bottle' into the abdomen and thighs by a non-medical practitioner
Se kildeExtracellular phosphatidylcholine functions as a noncanonical TLR4 activator to drive adipocyte lipolysis and apoptosis
Frontiers in Pharmacology · 3T3-L1 adipocytes exposed to phosphatidylcholine at 0-25 mg/mL
PubMed · 42137329Heterotopic ossification of the masseter muscle following injection lipolysis: A case report and review
Journal of Cranio-Maxillo-Facial Surgery · single case report, 35-year-old woman after jawline injection lipolysis
PubMed · 42242003
Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning.